Capital Advisors Ltd’s Revance Therapeutics, Inc. RVNC Stock Holding History

Capital Advisors Ltd’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-760	Closed	-$7K	–	1589
2023 Q4	$7K	Hold	760	–	–	﹤0.01%	774
2023 Q3	$9K	Hold	760	–	–	﹤0.01%	714
2023 Q2	$19K	Buy	+760	New	+$23.7K	﹤0.01%	588
2023 Q1	–	Sell	-760	Closed	–	–	1609
2022 Q4	$0	Buy	+760	New	+$17.4K	﹤0.01%	1713

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Advisors Ltd's RVNC Position: Q1 2024 in Review

Capital Advisors Ltd sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2024, closing a stake of 760 shares — an estimated $7K sold.

Capital Advisors Ltd first reported a position in RVNC in Q4 2022 and held it in 4 quarters. The position peaked at $19K in Q2 2023. 188 funds tracked by Wall St. Rank hold RVNC as of Q1 2024.

Capital Advisors Ltd reported no remaining Revance Therapeutics, Inc. position as of Q1 2024 after selling out during the quarter.
Capital Advisors Ltd sold 760 Revance Therapeutics, Inc. shares in Q1 2024, an estimated $7K.
Capital Advisors Ltd first reported a position in Revance Therapeutics, Inc. in Q4 2022 and held it in 4 quarters.
Capital Advisors Ltd's Revance Therapeutics, Inc. position peaked at $19K in Q2 2023.
188 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2024.

Based on Capital Advisors Ltd's 13F filing for Q1 2024, filed 18 Apr 2024.